Morning Seminar March 29, 2007

J Clin Oncol. 2007 Feb 1;25(4):356-61.
Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
Vassal G, Couanet D, Stockdale E, Geoffray A, Geoerger B, Orbach D, Pichon F, Gentet JC, Picton S, Bergeron C, Cisar L, Assadourian S, Morland B; French Society of Pediatric Oncology; United Kingdom Children's Cancer Study Group.

J Clin Oncol. 2007 Feb 1;25(4):362-9.
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH; Children's Oncology Group.

Morning Seminar March 27, 2007

Blood. 1992 Jun 15;79(12):3325-30.
The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children.
Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Lion T, Haas OA, Harbott J, Bannier E, Ritterbach J, Jankovic M, Fink FM, Stojimirovic A, Herrmann J, Riehm HJ, et al.

Morning Seminar March 23, 2007

Circulation. 2004 Jun 8;109(22):2749-54.
Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.
Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM.

Morning Seminar March 13, 2007

Cancer Sci. 2006 Nov 3; [Epub ahead of print]
Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts.
Masuda K, Hiraki A, Fujii N, Watanabe T, Tanaka M, Matsue K, Ogama Y, Ouchida M, Shimizu K, Ikeda K, Tanimoto M.

Morning Seminar March 8, 2007

ASH 2006, Part II